Neurocrine Biosciences | NBIX - Ordinary Share Capital



Neurocrine Biosciences reported $99M in Ordinary Share Capital for its fiscal quarter ending in June of 2025.


Ordinary Share Capital Change Date
AbbVie USD 18M 0 Dec/2024
Acadia Pharmaceuticals USD 167.36M 167.35M Jun/2025
Agios Pharmaceuticals USD 58.04M 57.96M Jun/2025
ALKERMES USD 165.05M 163.25M Jun/2025
Alnylam Pharmaceuticals USD 130.98M 129.67M Jun/2025
Amgen USD 538M 33.04B Jun/2025
Biogen USD 146.6M 146.5M Jun/2025
BioMarin Pharmaceutical USD 192M 191.81M Jun/2025
Cytokinetics USD 119.6M 119.48M Jun/2025
Dynavax Technologies USD 117.23M 117.11M Jun/2025
Exelixis USD 270.13M 269.86M Jul/2025
Gilead Sciences USD 1.24B 3M Jun/2025
Halozyme Therapeutics USD 117.62M 117.5M Jun/2025
Incyte USD 194.12M 193.93M Jun/2025
Ionis Pharmaceuticals USD 159.2M 159.04M Jun/2025
Neurocrine Biosciences USD 99M 0 Jun/2025
Pfizer USD 5.68B 5.2B Jun/2025
Prothena USD 53.83M 53.29M Jun/2025
Regeneron Pharmaceuticals USD 106.4M 106.4M Jun/2025
Repligen USD 562K 1000 Mar/2025
Sarepta Therapeutics USD 97.71M 97.7M Jun/2025
Teva Pharmaceutical Industries USD 1.15B 1.09B Jun/2025
Ultragenyx Pharmaceutical USD 96.35M 2.45M Jun/2025
Vertex Pharmaceuticals USD 256.3M 253.7M Jun/2025